Workflow
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
STOKStoke Therapeutics(STOK) ZACKS·2024-11-05 14:16

Company Performance - Stoke Therapeutics reported a quarterly loss of 0.47pershare,betterthantheZacksConsensusEstimateofalossof0.47 per share, better than the Zacks Consensus Estimate of a loss of 0.52, and an improvement from a loss of 0.55pershareayearago,representinganearningssurpriseof9.620.55 per share a year ago, representing an earnings surprise of 9.62% [1] - The company posted revenues of 4.89 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 41.65%, compared to revenues of 3.31millioninthesamequarterlastyear[2]−Overthelastfourquarters,StokeTherapeuticshassurpassedconsensusEPSestimatesfourtimesandtoppedconsensusrevenueestimatesthreetimes[2]StockPerformance−StokeTherapeuticsshareshaveincreasedapproximately149.13.31 million in the same quarter last year [2] - Over the last four quarters, Stoke Therapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Stoke Therapeutics shares have increased approximately 149.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 19.8% [3] - The current consensus EPS estimate for the upcoming quarter is -0.56 on revenues of 2.96million,andforthecurrentfiscalyear,itis−2.96 million, and for the current fiscal year, it is -2.10 on revenues of $14.82 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Stoke Therapeutics belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]